Celularity Inc (CELU)

$2.13 +0.09 (4.41%)
Market Cap 56.85M
Revenue (ttm) 54.22M
Net Income (ttm) -57.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -106.77%
Debt to Equity Ratio -1.70
Volume 92,200
Avg Vol 132,276
Day's Range N/A - N/A
Shares Out 26.69M
Stochastic %K 53%
Beta 0.75
Analysts Sell
Price Target $6.00

Company Profile

Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degene...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 768 2170
Address:
170 Park Avenue, Florham Park, United States
mf3rs
mf3rs Oct. 5 at 2:18 AM
$CELU Not celu https://www.nad.com/news/anti-aging-breakthrough-stem-cells-reverse-signs-of-aging-in-monkeys
0 · Reply
Nosay
Nosay Oct. 2 at 6:51 PM
$CELU guess who is headlining a conference in Saudi Arabia at the end of October. Who needs Saudi money anyways 🤗 https://fii-institute.org/conference/fii9-edition
0 · Reply
luckydog2
luckydog2 Oct. 2 at 11:45 AM
$CELU DefEYE - another game-changer in the works. https://www.reddit.com/r/CelularityNews/s/mZ3p7ZnR2j
0 · Reply
CharlieMungersghost
CharlieMungersghost Oct. 2 at 8:26 AM
$CELU for sure. Next financials should show no debt. And we're starting from lower expectations.
0 · Reply
FunCoupons00
FunCoupons00 Oct. 2 at 1:25 AM
$CELU for the OG’s you know we’re this is going
0 · Reply
CharlieMungersghost
CharlieMungersghost Oct. 1 at 3:46 PM
$CELU
0 · Reply
Andy_mc
Andy_mc Oct. 1 at 1:54 PM
$CELU Regn and Gild up today. I think if Regn passes $600 there will be a lot of FOMO about oncology names, it looks like a long term reversal, also XBI breaking $100.. Celu will occur to people... even though the Regn partnership has ended (which is a shame)
0 · Reply
highnihilism
highnihilism Oct. 1 at 12:56 PM
$CELU Celularity Trades: 5 | Total $: 235 | 0.03 × 90-Day Avg $: 7.8 K | Call $: 235 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $CVU Cpi Aerostructures Trades: 2 | Total $: 235 | 0.40 × 90-Day Avg $: 581 | Call $: 235 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $MNDO Mind C.T.I. Trades: 5 | Total $: 232 | 0.37 × 90-Day Avg $: 621 | Call $: 232 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $LAKE Lakeland Industries Trades: 2 | Total $: 230 | 0.02 × 90-Day Avg $: 11.3 K | Call $: 230 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
CharlieMungersghost
CharlieMungersghost Oct. 1 at 10:42 AM
$CELU come on bro! Better risk reward than that, now the debt has gone.
1 · Reply
GreatGP
GreatGP Oct. 1 at 12:51 AM
$CELU Lotto ticket
0 · Reply
Latest News on CELU
Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance

Sep 3, 2025, 8:00 AM EDT - 4 weeks ago

Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Aug 22, 2025, 5:30 PM EDT - 6 weeks ago

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt

Aug 18, 2025, 8:00 AM EDT - 6 weeks ago

Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

Jul 9, 2025, 8:30 AM EDT - 3 months ago

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies

Jul 1, 2025, 8:30 AM EDT - 3 months ago

Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies

Celularity Announces Chief Financial Officer Transition

Jun 10, 2025, 4:15 PM EDT - 4 months ago

Celularity Announces Chief Financial Officer Transition

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

Jun 2, 2025, 8:00 AM EDT - 4 months ago

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

Celularity Announces Full Year 2024 Operating and Financial Results

May 9, 2025, 9:15 AM EDT - 5 months ago

Celularity Announces Full Year 2024 Operating and Financial Results

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

Apr 25, 2025, 5:30 PM EDT - 5 months ago

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Apr 14, 2025, 8:00 AM EDT - 6 months ago

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Feb 25, 2025, 8:00 AM EST - 7 months ago

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

Feb 24, 2025, 8:00 AM EST - 7 months ago

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Dec 10, 2024, 8:00 AM EST - 10 months ago

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Dec 6, 2024, 8:00 AM EST - 10 months ago

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Celularity Inc. Announces Receipt of Nasdaq Notification

Nov 27, 2024, 5:00 PM EST - 11 months ago

Celularity Inc. Announces Receipt of Nasdaq Notification

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Nov 20, 2024, 8:30 AM EST - 11 months ago

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Oct 23, 2024, 8:30 AM EDT - 1 year ago

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Oct 18, 2024, 6:00 PM EDT - 1 year ago

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Oct 16, 2024, 5:15 PM EDT - 1 year ago

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Celularity Appoints Richard J. Berman to its Board of Directors

Aug 28, 2024, 4:45 PM EDT - 1 year ago

Celularity Appoints Richard J. Berman to its Board of Directors

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Aug 23, 2024, 5:00 PM EDT - 1 year ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 3, 2024, 8:38 AM EDT - 1 year ago

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

May 14, 2024, 9:15 AM EDT - 1 year ago

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

Celularity Inc. to Host Investor and Analyst Research & Development Day

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Celularity Inc. to Host Investor and Analyst Research & Development Day

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Apr 19, 2024, 5:30 PM EDT - 1 year ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Apr 18, 2024, 4:30 PM EDT - 1 year ago

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Apr 8, 2024, 9:00 AM EDT - 1 year ago

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Mar 26, 2024, 9:00 AM EDT - 1 year ago

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Mar 20, 2024, 9:15 AM EDT - 1 year ago

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

Mar 14, 2024, 9:15 AM EDT - 1 year ago

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Mar 12, 2024, 9:20 AM EDT - 1 year ago

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Mar 7, 2024, 9:35 AM EST - 1 year ago

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Celularity Announces 1-for-10 Reverse Stock Split

Feb 23, 2024, 4:10 PM EST - 1 year ago

Celularity Announces 1-for-10 Reverse Stock Split

Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Feb 14, 2024, 4:05 PM EST - 1 year ago

Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

Feb 1, 2024, 9:00 AM EST - 1 year ago

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions

Jan 25, 2024, 9:00 AM EST - 1 year ago

Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions

Celularity Releases CEO Letter to Shareholders

Jan 18, 2024, 1:40 PM EST - 1 year ago

Celularity Releases CEO Letter to Shareholders

Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

Jan 4, 2024, 1:00 PM EST - 1 year ago

Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023

Jan 3, 2024, 12:00 PM EST - 1 year ago

Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023

Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification

Oct 18, 2023, 9:00 AM EDT - 2 years ago

Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification

Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

Sep 7, 2023, 4:10 PM EDT - 2 years ago

Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

Aug 29, 2023, 9:00 AM EDT - 2 years ago

Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

Celularity Inc. Announces $3 Million Registered Direct Offering

Jul 27, 2023, 9:07 AM EDT - 2 years ago

Celularity Inc. Announces $3 Million Registered Direct Offering

Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications

Jul 27, 2023, 9:00 AM EDT - 2 years ago

Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications

Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies

Jul 18, 2023, 9:00 AM EDT - 2 years ago

Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies

Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics

Jun 29, 2023, 4:05 PM EDT - 2 years ago

Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics

mf3rs
mf3rs Oct. 5 at 2:18 AM
$CELU Not celu https://www.nad.com/news/anti-aging-breakthrough-stem-cells-reverse-signs-of-aging-in-monkeys
0 · Reply
Nosay
Nosay Oct. 2 at 6:51 PM
$CELU guess who is headlining a conference in Saudi Arabia at the end of October. Who needs Saudi money anyways 🤗 https://fii-institute.org/conference/fii9-edition
0 · Reply
luckydog2
luckydog2 Oct. 2 at 11:45 AM
$CELU DefEYE - another game-changer in the works. https://www.reddit.com/r/CelularityNews/s/mZ3p7ZnR2j
0 · Reply
CharlieMungersghost
CharlieMungersghost Oct. 2 at 8:26 AM
$CELU for sure. Next financials should show no debt. And we're starting from lower expectations.
0 · Reply
FunCoupons00
FunCoupons00 Oct. 2 at 1:25 AM
$CELU for the OG’s you know we’re this is going
0 · Reply
CharlieMungersghost
CharlieMungersghost Oct. 1 at 3:46 PM
$CELU
0 · Reply
Andy_mc
Andy_mc Oct. 1 at 1:54 PM
$CELU Regn and Gild up today. I think if Regn passes $600 there will be a lot of FOMO about oncology names, it looks like a long term reversal, also XBI breaking $100.. Celu will occur to people... even though the Regn partnership has ended (which is a shame)
0 · Reply
highnihilism
highnihilism Oct. 1 at 12:56 PM
$CELU Celularity Trades: 5 | Total $: 235 | 0.03 × 90-Day Avg $: 7.8 K | Call $: 235 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $CVU Cpi Aerostructures Trades: 2 | Total $: 235 | 0.40 × 90-Day Avg $: 581 | Call $: 235 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $MNDO Mind C.T.I. Trades: 5 | Total $: 232 | 0.37 × 90-Day Avg $: 621 | Call $: 232 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $LAKE Lakeland Industries Trades: 2 | Total $: 230 | 0.02 × 90-Day Avg $: 11.3 K | Call $: 230 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
CharlieMungersghost
CharlieMungersghost Oct. 1 at 10:42 AM
$CELU come on bro! Better risk reward than that, now the debt has gone.
1 · Reply
GreatGP
GreatGP Oct. 1 at 12:51 AM
$CELU Lotto ticket
0 · Reply
FunCoupons00
FunCoupons00 Sep. 30 at 4:44 PM
$CELU Soon 🌙
0 · Reply
CharlieMungersghost
CharlieMungersghost Sep. 30 at 9:17 AM
$CELU let's get third quarter earnings on time Hariri. That would be a huge catalyst imo.
0 · Reply
CharlieMungersghost
CharlieMungersghost Sep. 29 at 1:27 PM
$CELU 🤣 🤣 🤣
0 · Reply
Andy_mc
Andy_mc Sep. 27 at 2:28 PM
$CELU Thoughts on the patent Wisdom man posted to Reddit?
2 · Reply
StockScanners
StockScanners Sep. 27 at 4:25 AM
$CELU keep watch if this holds above 2.14
0 · Reply
Nosay
Nosay Sep. 26 at 1:32 PM
$CELU 700k order at 1.90 3 mins before market open? Love to know what the heck that was.
2 · Reply
TwongStocks
TwongStocks Sep. 25 at 12:13 PM
NJEDA held their monthly board meeting on Sept 10 & approved 23 applications for their Net Operating Loss (NOL) program. https://www.njeda.gov/wp-content/uploads/2025/09/September-10-2025-EDA-Board-Book.pdf (pages 256-260) New Jersey's NOL program allows small tech and bio companies sell their NOLs to profitable companies for cash. The profitable companies buy the NOLs to get a state tax break. Some bios that were approved for the calendar year 2025 NOL Program: $CELU $CTSO $CTXR $LSTA $SNGX
2 · Reply
CharlieMungersghost
CharlieMungersghost Sep. 25 at 6:52 AM
$CELU me too. Too risky not to.
1 · Reply
ERQ
ERQ Sep. 24 at 8:23 PM
$CELU Against my better judgement I added a few more shares.
0 · Reply
CharlieMungersghost
CharlieMungersghost Sep. 22 at 10:19 AM
$CELU I think they'll get september report out on time That and the debt should set us up for more institutionals
1 · Reply
Arcides
Arcides Sep. 19 at 9:31 PM
$CELU 10 days hugging 200dma, high volume today. about 3X average.
0 · Reply
CharlieMungersghost
CharlieMungersghost Sep. 19 at 3:14 PM
$CELU extinguishing their debt was a crazy move bro. Wherever we go on this pullback, we fly after it! Matter of time...
0 · Reply